In this article
  1. What happened
  2. How a personalised cancer vaccine works
  3. The results in numbers
  4. Why it matters
  5. What comes next
  6. Frequently asked questions

Updated 23 October 2026. This is a developing story; we will update it as new official information is published.

A personalised melanoma vaccine developed by Moderna and Merck reduced the risk of the cancer coming back, or death, by 42% in a Phase 3 trial, the companies said on 22 October. The mRNA treatment, called intismeran autogene, was given with the immunotherapy drug Keytruda to people whose melanoma had been removed by surgery. It is not yet approved, and the companies say they are now engaging with regulators.

Key facts

  • 42% lower risk of recurrence or death with intismeran plus Keytruda than Keytruda alone (hazard ratio 0.58).
  • 82.2% vs 70.0%: share of patients alive and cancer-free after two years.
  • 1,137 patients with stage IIB to IV melanoma removed by surgery took part.
  • Not yet approved: overall survival data are not mature; regulators have not ruled.

What happened

Merck and Moderna presented detailed results from the INTerpath-001 trial at the European Society for Medical Oncology (ESMO) Congress 2026, in its Presidential Symposium, and say the study has been accepted for publication in The New England Journal of Medicine. After a median follow-up of just over two years, adding the vaccine to Keytruda cut the risk of recurrence or death by 42% and the risk of the cancer spreading to distant organs, or death, by 38%.

The trial was randomised and double-blind: patients and doctors did not know who got the vaccine and who got a placebo. Two patients in three received the vaccine.

How a personalised cancer vaccine works

Unlike a flu shot, this is a treatment, not a way to prevent cancer in healthy people. Doctors take a sample of the patient’s tumour and normal DNA and look for mutations unique to that cancer. Moderna then makes an mRNA medicine coding for up to 34 of those mutated proteins, called neoantigens. The body reads the mRNA, shows the proteins to the immune system and trains T cells to attack cancer cells carrying them. Our explainer on how vaccines work covers the basics of training the immune system.

The results in numbers

MeasureVaccine + KeytrudaKeytruda alone
Alive without recurrence at 2 years82.2%70.0%
Alive without distant spread at 2 years88.5%80.2%
Serious (grade 3 to 5) treatment side effects14.2%13.4%
Patients755380
Source: Merck and Moderna, INTerpath-001 results announced 22 October 2026.

The most common side effects with the vaccine were fever (52.2%), pain at the injection site (51.0%) and tiredness (38.5%). The companies say the safety profile was consistent with earlier studies and no new safety signals were seen.

One detail matters for patients: in the first six months, the vaccine group did no better than Keytruda alone, which fits the time needed to make and give the personalised doses. After six months, the companies report a 58% reduction in risk of recurrence or death.

Why it matters

Merck calls INTerpath-001 the first Phase 3 study to show a clinically meaningful improvement over standard-of-care Keytruda in patients whose melanoma has been removed. Melanoma often returns within two years of surgery, according to the companies, and spreads to organs such as the lungs, liver and brain. The US National Cancer Institute’s melanoma treatment guide explains the stages and current options.

The trial is registered on ClinicalTrials.gov (NCT05933577). Merck and Moderna are also testing the approach in lung cancer, with three Phase 3 trials under way.

What comes next

The companies say they are talking to regulators about approval, and the trial continues in order to measure overall survival, which shows a favourable trend but is not yet mature. No approval date has been announced. Costs and coverage are unknown; for how health costs reach patients, see our report on rising employer health insurance costs.

Medical note: This article is for general information and is not medical advice. Talk to your oncologist about treatment options and clinical trials.

Frequently asked questions

Is there a vaccine for melanoma?

Not an approved one yet. Moderna and Merck’s intismeran autogene succeeded in a Phase 3 trial and the companies are engaging with regulators.

What is the Moderna melanoma vaccine?

Intismeran autogene (also called mRNA-4157 or V940), a personalised mRNA therapy made for each patient from their own tumour, given alongside Keytruda after surgery.

When will the melanoma vaccine be FDA approved?

No date has been announced. The companies say they are engaging with regulatory authorities based on the Phase 3 results.

Does the melanoma vaccine prevent cancer?

No. It is a treatment for people who have had high-risk melanoma removed, designed to lower the chance it returns.

Read more in our Medicine section.

Sources

  1. Merck: INTerpath-001 Phase 3 results at ESMO 2026 (with Moderna), 22 October 2026
  2. ClinicalTrials.gov: INTerpath-001 (NCT05933577)
  3. National Cancer Institute: Melanoma treatment (PDQ)